Motivators, Barriers and Clinical Correlates of Physical Activity in Parkinson Disease
Objective: To characterize physical activity levels as well as barriers and motivators for exercise in US military Veterans with Parkinson disease (PD). Background: Physical activity…Nurr1 gene: A new research target for Parkinson’s disease
Objective: The objective of our study is to determine if Nurr1 gene, a transcription factor essential for dopamine (DA) neuron development and survival, is a…T lymphocytes in Parkinson’s disease pathogenesis and therapy: A systematic review
Objective: A systematic literature review was conducted to synthesize the current state of knowledge on the role of T lymphocytes in Parkinson’s disease (PD) pathology…Activation of chaperone-mediated autophagy reduces oligomeric alpha-synuclein accumulation in LRRK2(R1441G) knockin mouse model of Parkinson’s disease (PD)
Objective: To determine age-dependent accumulation of oligomeric alpha-synuclein in the brain of aged LRRK2(R1441G) knockin mice; and to explore whether activation of chaperone-mediated autophagy (CMA)…Enhancing protein palmitoylation is protective in alpha-synuclein dependent cytotoxicity
Objective: To determine if enhancement of protein palmitoylation benefits alpha-synuclein (aS) dependent vesicular trafficking defects and cytotoxicity. Background: Recent studies suggest that vesicular trafficking defects…Measuring salivary cortisol levels in persons with Parkinson’s disease (PD)
Objective: To better characterize the relationship between salivary cortisol and psychological stress in persons with Parkinson’s disease (PD). Background: Psychological stress is known to exacerbate…PPMI driven sample size estimation for clinical trials in Parkinson’s disease
Objective: To utilize clinical, imaging and CSF data from the Parkinson’s Progression Markers Initiative (PPMI) to estimate the sample size for disease modification studies in…A Psychometric Analysis of the MDS UPDRS-II and III in Early Parkinson’s disease: Do the Numbers Add Up?
Objective: Our objective was to explore the psychometric evidence for the use of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part II…The Small Molecule Alpha-Synuclein Misfolding Inhibitor, NPT200-11, Produces Multiple Benefits in an Animal Model of Parkinson’s Disease
Objective: To evaluate effects of NPT200-11 on Parkinson’s disease (PD)-relevant outcomes including alpha-synuclein pathology, neurodegenerative markers and motor performance in transgenic mouse models of PD.…A Study to Evaluate the Efficacy of PRX002/RG7935 in Participants With Early Parkinson’s Disease (PASADENA) – Study Design
Objective: To evaluate the efficacy of the anti-alpha-synuclein monoclonal antibody PRX002/RG7935 in a proof-of-concept Phase 2 study in patients with early Parkinson’s disease (PD). Background:…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 16
- Next Page »